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Inhibition of VEGF activity or disabling the 
function of VEGF receptors is therefore a 
potential strategy for improving radiation 
outcome. The VEGF blockade alone has been 
shown to inhibit both tumor growth and 
metastasis in a variety of animal tumor mod-
els11. Currently, three approaches are in clinical 
development to target the VEGF/VEGFR-sig-
naling pathway: (1) monoclonal antibodies 
directed against VEGF or its receptors12–15, 
(2) small molecule inhibitors of the VEGFR-
2 tyrosine kinase enzyme16–19, and (3) soluble 
decoy receptors created from the VEGFR1 
receptor which selectively inhibit VEGF20, 21. 
The relative benefits of these strategies have yet 
to be determined clinically.
Tumor cures are rare when VEGF blockers 
are used as the sole method of treatment; in 
general, antiangiogenics appear to work best 
in combination with cytotoxic therapies22. 
A number of preclinical studies suggest that 
radiotherapy in combination with VEGF
targeting agents enhances the radiotherapeutic 
ratio (see reviews;23, 24). The best way to incor-
porate VEGF inhibition strategies into current 
radiotherapy regimens remains unknown.
Because of the role that angiogenesis plays in 
the radiation response, the objective of this 
study was to determine whether VEGF Trap 
(Regeneron Pharmaceuticals, Tarrytown, NY), 
a potent anti-VEGF angiogenesis inhibitor 
that traps circulating VEGF in the blood-
stream and in the extracellular space, would 
enhance radiation therapy in the human U87 
glioblastoma (GBM) tumor model. Because 
GBM tumors are among the most radiore-
sistant and vascular of neoplasms and are 
known to secrete high levels of VEGF25, U87 
GBM was deemed an appropriate model to 
assess the effects of VEGF Trap and radiation. 
It was hypothesized that inhibition of VEGF 
signaling by VEGF Trap would improve the 
human U87 glioblastoma model response 
to radiotherapy.
The administration of decoy soluble VEGF 
receptors has been found to be a very effective 
way to block the VEGF signaling pathway26–29. 
VEGF Trap is a unique human fusion protein 
comprising portions of human VEGF recep-
VEGF Trap In Combination With 
Radiotherapy Improves Tumor
Control In U87 Glioblastoma
Purpose 
To determine the effect of vascular endothelial growth factor VEGF Trap (Regeneron 
Pharmaceuticals, Tarrytown, NY), a humanized soluble vascular endothelial growth factor 
(VEGF) receptor protein, and radiation (RT) on tumor growth in U87 glioblastoma xenografts 
in nude mice.
Methods and Materials
U87 cell suspensions were implanted subcutaneously into hind limbs of nude mice. VEGF Trap 
(2.5–25 mg/kg) was administered every 3 days for 3 weeks alone or in combination with a single 
dose of 10 Gy or fractionated RT (3 x 5 Gy). In addition, three scheduling protocols for VEGF 
Trap plus fractionated RT were examined.
Results
Improved tumor control was seen when RT (either single dose or fractionated doses) was 
combined with the lowest dose of VEGF Trap (2.5 mg/kg). Scheduling did not significantly 
affect the efficacy of combined therapy. Although high-dose VEGF Trap (10 mg/kg or 25 mg/kg) 
significantly reduced tumor growth over that of RT alone, there was no additional benefit to 
combining high-dose VEGF Trap with RT. 
Conclusions 
Vascular endothelial growth factor Trap plus radiation is clearly better than radiation alone 
in a U87 subcutaneous xenograft model. Although high doses of VEGF Trap alone are highly 
efficacious, it is unclear whether such high doses can be used clinically without incurring normal 
tissue toxicities. Thus, information on lower doses of VEGF Trap and ionizing radiation is of 
clinical relevance. © 2007 Elsevier Inc. 
Key Words: Vascular endothelial growth factor Trap, Radiotherapy, Anti-angiogenic, 
U87 glioblastoma.
Introduction
Radiation (RT) therapy is an important treatment modality for many cancers; however, its therapeutic 
success is impeded by dose-limiting normal tissue toxicities and the development of radioresistance. 
Recent studies emphasize the importance of the tumor microvascular response in addition to the 
tumor cell response in determining tumor radioresistance1, 2. Ionizing radiation can directly induce 
endothelial cell apoptosis1, 3, which can inhibit tumor growth and lead to radiosensitization. However, 
in opposition to endothelial cell damage, radiation also induces signal transduction cascades, which 
contribute to radiation resistance through upregulation of proliferative, survival, and angiogenic 
pathways4. In particular, radiation induces vascular cytokines, such as vascular endothelial growth 
factor (VEGF)5, 6, one of the most potent endothelial cell survival factors7, which functions as a 
powerful antiapoptotic factor for endothelial cells in new blood vessels8, 9. Radiation-induced VEGF 
results in tumor radioresistance through vascular radioprotection2, 10.
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tor 1 (VEGFR1) and human VEGF receptor 2 (VEGFR2) extracellular 
domains fused to the constant region (Fc) of human IgG121. VEGF Trap 
has greater affinity for the VEGF ligand than anti-VEGF monoclonal 
antibodies (mab) do (dissociation constant <1 pMol/L for VEGF Trap 
vs. 0.1–10 nMol/L for mab)30. VEGF Trap has been shown to inhibit 
neoangiogenesis and tumor growth in tumor xenografts and metastases, 
as well as reduce the formation of malignant ascites14, 21, 31.
Methods and Materials
Analysis of VEGF levels in U87 tumor cells in culture 
U87 glioblastoma cells (American Type Culture Collection) were 
maintained in alpha MEM (Sigma-Aldrich, St. Louis, MO) with 10% 
fetal bovine serum (Atlanta Biologicals, Norcross, GA). U87 cells were 
irradiated at doses between 2 and 20 Gy in the presence or absence of 
40 nM VEGF Trap and incubated for 48 h. Using a commercially avail-
able human VEGF immunoassay kit (R&D Systems, Minneapolis, MN), 
VEGF was assayed from culture supernatants.
Animal and tumor model
U87 cell suspensions (5 x 105 cells in 100 μL phosphate buffered saline) 
were implanted subcutaneouly (SC) into the right hind limbs of athymic 
NCR NUM mice (Taconic Farms, Hudson, NY). A SC xenograft model 
was chosen to facilitate radiation dosing and ease of tumor measure-
ments in the more than 200 mice measured in this study. Mice were not 
pretreated before tumor implantation. U87 tumors were allowed to grow 
for approximately 14 to 18 days until reaching an approximate diameter 
of 4 to 5 mm before treatment.
Drug and irradiation treatment
In an initial pilot study, VEGF Trap was administered at two doses, a high 
dose (25 mg/kg) or low dose (2.5 mg/kg), every 3 days, up to 3 weeks, 
with or without a single dose of radiation (10 Gy) given on Day 0. VEGF 
Trap was administered every 3 days because it has a half-life of 72 h in 
mouse serum (drug pharmacokinetics communicated by Regeneron). 
Drug was administered 2 h before radiation. When fractionated radio-
therapy was used, VEGF Trap was combined at 2.5 mg/kg (low dose) 
or 10 mg/kg (intermediate dose) with fractionated radiotherapy (three 
fractions of 5 Gy each) on Days 0, 1, and 2. Scheduling of VEGF Trap was 
either 1 week before fractionated radiation and continuing for a period 
of 3 weeks, concurrent with radiation and continuing for a period of 3 
weeks, or 3 days postradiation treatment and continuing for a period 
of 3 weeks. Thus, the total number of drug doses was constant for each 
schedule (see Fig. 1 for dose and irradiation scheduling protocol).
Irradiation was performed on anesthetized mice using an X-ray machine 
(Gulmay Medical, Bethel, CT) operating at 250 kV, 10 mA, with a 2-mm 
aluminum filtration. The effective photon energy was ≈90 keV. Mice 
were anesthetized with a combination of ketamine and acepromazine at a 
concentration of 75 mg/kg and 0.35 mg/kg, respectively. Each mouse was 
confined in a lead casing with its tumor-bearing leg extended through 
an opening on the side to allow the tumor to be irradiated locally.
Radiation was administered as three daily fractions of 5 Gy each as 
described earlier.
Tumor size was measured 4 to 5 times per week after treatment by direct 
measurement with calipers and calculated by the formula [(smallest 
diameter (2) x widest diameter) / 2]. Tumors were not allowed to grow 
beyond 2,000 mm3 in accordance with Institutional Animal Care and Use 
Committee regulations.
Positron emission tomography imaging
The MOSAIC PET scanner (Philips Medical Systems, Brisbane, CA) 
was used for PET studies. Before imaging, mice were anesthetized with 
ketamine (75 mg/kg) and acepromazine (0.35 mg/kg) via a SC injection. 
Once anesthetized 0.3 to 0.5 μCi of 18-fluorodeoxyglucose (FDG) was 
administered intravenously. Sixty to seventy min were allowed for uptake 
of the tracer. Mice were placed in a 50-mL specimen tube to facilitate 
multimodality stereotactic positioning. The PET data were acquired in 
a single position for 15 min. Volumes of interest (VOIs) were defined by 
drawing multislice regions of interest (ROIs) on the PET images using 
50% of the full-width-at-half-maximum (FWHM) of the tumor to deter-
mine the tumor boundary. In the case of tumors with a core lacking FDG 
uptake, the tumor and core boundaries were defined by 50% FWHM of 
each wall adjacent to the core. Mice were divided into three groups (n 
= 3–6 animals per group): untreated; low-dose VEGF Trap–treated (2.5 
mg/kg), and highdose VEGF Trap–treated (10 mg/kg).
21147012
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VEGF Trap + Fractionated RT  (3 x 5 Gy)
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Figure 1. Scheduling protocols for vascular endothelial growth 
factor (VEGF) Trap administration in combination with radiation 
(RT). VEGF Trap was given at 2.5, 10, or 25 mg/kg every 3 days in 
four schedules: (I) VEGF Trap given on Day 0 concurrent with a 
single dose of RT (10 Gy) and continued up to 3 weeks; (II) VEGF 
Trap given on day –7 before RT (3 x 5 Gy) and continued for 3 
weeks; (III) VEGF Trap given on Day 0 concurrent with RT (3 x 5 
Gy) and continued up to 3 weeks; (IV) VEGF Trap given on Day 3 
post RT (3 x 5 Gy) and continued up to 3 weeks. All three protocols 
received the same number of drug doses. Day 0 was always the start 
of radiation.
BODINEJOURNAL14
Immunohistochemistry
Platelet–endothelial cell adhesion molecule 1 (PECAM-1) immunos-
taining for microvessel density (MVD): control, radiation-treated, 
VEGF Trap–treated tumors, and VEGF Trap plus radiation–treated 
tumors were immunostained with a rat antimouse PECAM-1 mAb (BD 
Biosciences, Boston, MA) and a rabbit antirat biotinylated secondary 
antibody (Vector Labs, Burlingame, CA). Enhanced horseradish per-
oxidase–conjugated streptavidin and a substrate chromogen, AEC 
(3-amino-9-ethyl carbazole), were used to visualize the signal. (HIS-
TOSTAIN-PLUS kit, Invitrogen, Carlsbad, CA); slides were examined 
with a Nikon Eclipse E600 microscope to calculate MVD, the area 
occupied by the PECAM-1-positive microvessels, and total tissue area 
per section were quantified using National Institute of Health Image J 
software. Microvessel density was expressed as percent area of blood 
vessels stained per tissue section. Areas of necrosis were excluded 
from calculations. Four or five high-power fields were identified on 
each section with three to four sections per tumor and two tumors
per endpoint.
Statistical analysis of tumor growth
Tumor size measurements over time were obtained from the following 
groups: control; radiation alone; VEGF Trap, low dose (2.5 mg/kg), inter-
mediate dose (10 mg/kg), or high dose (25 mg/kg); and the correspond-
ing two radiation plus VEGF Trap combinations (n = 10–14 animals per 
group). Tumor growth over the entire study follow-up period was mod-
eled via mixed-effects linear regression. This approach fits a “random” 
growth curve to each animal’s data and then statistically “averages” these 
curves within each treatment group to estimate an overall “fixed effect” 
for each group. It also properly handles unbalanced data (i.e., different 
number of measurements for different animals) and takes into account 
the correlation of each animal’s measurements over time. Because tumors 
typically grow exponentially, the base-10 logarithm of tumor volume was 
modeled as a function of time and treatment. The interpretation of the 
linear model for the log of tumor volume is in terms of geometric means 
and geometric mean ratios (while the usual interpretation of a regression 
model for an untransformed outcome is in terms of arithmetic means and 
mean differences). The fitted linear growth curves fitted the data well. In 
addition, an allowance was made for the variance of the random effects to 
differ across groups to account for the larger variability of measurements 
in certain treated groups. All statistical analyses were conducted in SAS 
8.2 (SAS Institute, Cary, NC, 1999–2001).
The mixed-effects regression has multiple advantages over analyses of 
tumor growth delay that typically compare groups with respect to the 
average time it takes tumors to reach some arbitrary size (e.g., 2,000 
mm3). First, mixed-effects regression yields more general parameters 
of interest, such as average daily tumor growth rate and doubling time.
Second, it can investigate (if necessary) treatment interactions and non-
linear patterns of tumor growth. Finally, it is more efficient because it 
used the repeated tumor size measurements obtained over the entire 
study period.
Results
Effect of VEGF Trap and radiation on VEGF secretion in U87 cells 
in culture
Levels of VEGF increased in U87 culture supernatants in a dose-depen-
dent manner following irradiation (Fig. 2). The addition of VEGF Trap 
(40 nM) reduced free VEGF in the supernatant to undetectable levels.
Effect of VEGF Trap and radiation on U87 tumor growth inhibition
The linear models for the log-transformed tumor growth fitted the data 
quite well in all groups. The raw data for all treatment groups with regres-
sion lines are plotted in Figs. 3 through 6 with corresponding Tables 1 
through 4. The average daily percent increase in tumor volume for the 
untreated control group was consistent across all protocols and ranged 
between 27% and 31%, corresponding to a tumor doubling time between 
2.5 and 3.0 days (Tables 1–4). Radiation alone (both single or fractionated 
doses) or VEGF Trap alone (all doses) significantly reduced the tumor 
growth rate compared with control (p < 0.001, Figs. 3–6, Tables 1–4). 
Results with VEGF Trap in combination with single dose or fractionated 
radiotherapy are now summarized.
Effect of VEGF Trap and single dose radiation (10 Gy) on U87 tumor 
growth inhibition 
Table 1 presents tumor growth data based on the mixed-effects linear 
regression analysis described in Methods and Materials, and Fig. 3 pres-
ents the original animal data. In this experiment, a low dose of VEGF 
Trap (2.5 mg/kg) initiated concurrently with a single dose of 10 Gy was 
compared with a 10x higher dose of VEGF Trap (25 mg/kg) plus 10 Gy. 
The six groups are compared in terms of average daily tumor growth 
and doubling time. It can be seen from Table 1 and Fig. 3 that both low-
dose and high-dose VEGF Trap were effective inhibitors of daily percent 
increase in tumor volume (%Δ = 15% and 5%, respectively, vs. 31% for 
controls, p = 0.001). Although low-dose VEGF Trap was not significantly 
better than 10-Gy treatment alone, the combination of low-dose VEGF 
Trap and 10 Gy slowed daily tumor growth (%Δ = 12% vs. 18% for 10 
Gy alone and 15% for low VEGF Trap alone). Thus, a less than additive 
enhancement in tumor control over either modality alone was observed. 
High-dose VEGF Trap, as a single treatment modality, was highly effec-
tive in slowing daily percent increase in tumor volume (5% vs. 18% for 
10 Gy). Its efficacy was not improved by the addition of 10 Gy. This study 
Control
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Figure 2. Effect of vascular endothelial growth factor (VEGF) 
Trap and radiation on VEGF secretion in U87 cells in culture. U87 
cells were irradiated at doses between 2 and 20 Gy in the presence 
or absence of 40 nM VEGF Trap. Cell culture supernatants were 
assayed for VEGF secretion 48 h following treatment. VEGF secre-
tion was undetectable in presence of 40 nM VEGF Trap.
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Figure 3. Effect of vascular endothelial growth factor (VEGF) Trap combined with single-dose radiation (10 Gy) on tumor growth in U87GBM. 
Individual mouse data for six treatment groups (n = 10–12 animals per group). VEGF Trap was given at 2.5 or 25 mg/kg starting on Day 0, 
concurrent with radiation and continuing every 3 days for 3 weeks (see schedule I, Fig. 1).
Radiotherapy
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Figure 4. Effect of vascular endothelial growth factor (VEGF) Trap initiated before fractionated radiation (3 x 5 Gy) on tumor growth in U87 GBM. 
Individual mouse data for 6 treatment groups (n = 10–14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day –7 and continuing 
every 3 days for 3 weeks (see schedule II, Fig. 2).
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Figure 5. Effect of vascular endothelial growth factor (VEGF) Trap sequenced concurrent with fractionated radiation (3 x 5 Gy) on tumor Growth in 
U87 GBM. Individual mouse data for six treatment groups (n = 10–14 animals per group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 0 
and continuing every 3 days for 3 weeks (see schedule III, Fig. 3).
BODINEJOURNAL18
Figure 6. Effect of vascular endothelial growth factor (VEGF) Trap sequenced post–fractionated radiation (3 x 5 Gy) on tumor Growth in U87 GBM. 
Individual mouse data for six treatment groups (n = 10–14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 3 and continuing 
every 3 days for 3 weeks (see schedule IV, Fig. 4).
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Table 1. Effect of VEGF Trap combined with single-dose radiation: Summary of tumor growth (Schedule I)
Treatment  %Δ (95% CI)  T2x  p values
Control (human FC protein)  31.0  (27–35)  2.6
RT (10 Gy)  18.0  (15–21)  4.2  0.001 vs. control, 0.19 vs. VEGF Trap (low)
VEGF Trap (2.5 mg/kg) 15.0  (13–28)  4.9  0.001 vs. control, 0.19 vs. RT alone
VEGF Trap (25 mg/kg)  5.0  (2–7)  15.2  0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGF Trap (low)
VEGF Trap (2.5mg/kg) + RT  12.0  (9–14)  6.3  0.003 vs. RT, 0.06 vs. VEGF Trap (low)
VEGF Trap (25 mg/kg) + RT  5.0  (2–7)  15.5  0.001 vs. RT, 0.417 vs. VEGF Trap (high), 0.96 vs. VEGF Trap (low) + RT
Abbreviations: %Δ = daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
Table 2. VEGF Trap initiated before fractionated radiation: Summary of tumor growth (Schedule II)
Treatment  %Δ (95% CI)  T2x  p values
Control (human FC protein)  27.0  (23–31)  3.0
RT (3 x 5 Gy)  11.0  (8–15)  6.5  0.001 vs. control, 0.59 vs. VEGF Trap (low), 0.027 vs. VEGF Trap (high)
VEGF Trap 2.5 mg/kg)  12.0  (10-15)  5.9  0.001 vs. control, 0.59 vs. RT
VEGF Trap 10 mg/kg) 7.0  (4–9) 11 0.001 vs control, 0.027 vs. RT, 0.001 vs. VEGF Trap (low)
VEGF Trap (low) + RT  7.0  (4–9)  10.6  0.034 vs. RT, 0.004 vs. VEGF Trap (low)
VEGF Trap (high) + RT  5.0  (2–7)  15.3  0.002 vs. RT, 0.33 vs. VEGF Trap (high)
Abbreviations: %Δ = daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
suggests that low-dose VEGF Trap in combination with single-dose 
radiation has an enhanced effect on tumor cell kill. It was thought that 
this enhancement might be improved by varying dose and scheduling 
protocol. Additional studies were carried out in which low-dose VEGF 
Trap at 2.5 mg/kg was compared with an intermediate dose of 10 mg/kg 
(because VEGF Trap at 25 mg/kg appeared to have masked any addi-
tional benefit of radiation in enhancing tumor control) in combination 
with a more clinically relevant fractionated radiotherapy protocol. The 
results of these studies are reported in the following sections.
Effect of VEGF Trap and fractionated radiation on U87 tumor growth 
inhibition 
VEGF Trap given before fractionated radiation: in this protocol, VEGF 
Trap was administered 7 days before radiation. The analyses allowed for 
separate tumor growth rates in the first and second periods (preradiation: 
Days –7 to 0; postradiation: Days 0+) for the groups that received radia-
tion. The study’s main aim was to compare tumor growth rates across treat-
ment groups in the latter period, when all treatments had been applied. 
Table 2 summarizes the results of the tumor growth modeling analyses 
during this main study phase, and Fig. 4 presents the original animal data. 
The low-dose VEGF Trap group (2.5 mg/kg every third day, starting at 
Day –7) demonstrated a reduction in daily percent increase in tumor 
volume (12% vs. 27% for control; p = 0.001) that was similar to the first 
single-dose radiation study, whereas the high-dose VEGF Trap group (10 
mg/kg every third day, starting at Day –7) had an even stronger effect 
(7%) that, again, was similar in trend to the first study. In the radiation 
only group, tumor daily growth was slowed to 11% (p < 0.001 vs. control). 
Although low-dose VEGF Trap was comparable to radiation alone (p = 
0.59), the combination of low-dose VEGF Trap with radiation (7% average 
daily percent increase in tumor volume, Table 1) was significantly better 
than either radiation alone (p = 0.036) or low-dose VEGF Trap alone (p 
< 0.005). The combination of high-dose VEGF Trap with radiation (5% 
average percent daily increase in tumor volume) was also significantly
better than radiation alone (p = 0.002) but not significantly better than high 
dose VEGF Trap alone (p = 0.33).
VEGF Trap given concurrently with fractionated radiation: Table 3 
summarizes the results of the tumor growth modeling analyses based 
on original animal data shown in Fig. 5. High-dose VEGF Trap was 
significantly better than radiation in reducing daily percent increase in 
tumor volume (8.5% vs. 16.1% for radiation, p = 0.001). The combina-
tion of low-dose VEGF Trap with radiation (12% average daily increase 
in tumor volume) was significantly better than either radiation alone 
(p = 0.029) or low-dose VEGF Trap alone (p = 0.012). The combination 
of high-dose VEGF Trap (10 mg/kg) with radiation (7% average daily 
increase in tumor volume) was also significantly better than radiation 
alone (p = 0.001) but not high-dose VEGF Trap alone (p = 0.417).
VEGF Trap given postradiation: Table 4 summarizes the results of the 
tumor growth modeling analyses based on original animal data shown 
in Fig. 6. The results of this schedule followed the same pattern as seen 
in the previous two schedules with fractionated radiation as well as the 
first experiment with single-dose radiation. The benefit of combining 
VEGF Trap with radiation compared with single-modality treatments 
was once again seen with low-dose VEGF Trap plus radiation. High-dose 
VEGF Trap at 10 mg/kg plus radiation significantly reduced percent daily 
increase in tumor volume when compared with radiation alone but was 
not significantly different from VEGF Trap alone (p = 0.187).
In summary, improved tumor control was seen when radiation (either 
single dose or fractionated doses) were combined with the lowest dose 
of VEGF Trap (2.5 mg/kg) used in these studies. Scheduling did not sig-
nificantly affectthe efficacy of combined therapy. The relative benefits 
of combined low-dose VEGF Trap plus fractionated radiation relative 
to radiation as judged by percent reduction in average daily increase in 
tumor volume were 36% for VEGF Trap given before radiation, 27% for 
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Table 3. Trap sequenced concurrently with radiation: Summary of tumor growth (Schedule III)
Treatment  %Δ (95% CI)  T2x  p values
Control (human FC protein)  27.0  (24–30)  2.9
RT (3 x 5 Gy)  16.0  (13–19)  4.6  0.001 vs. control, 0.729 vs. VEGF Trap (low), 0.001 vs. VEGF Trap (high)
VEGF Trap (2.5 mg/kg)  17.0  (14–19)  4.5  0.001 vs. control, 0.729 vs. RT alone
VEGF Trap (10 mg/kg)  8.5  (6–11)  8.5  0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGT Trap (low)
VEGF Trap (low) + RT  12.0  (9–14)  6.3  0.020 vs. RT, 0.008 vs. VEGF Trap (low)
VEGF Trap (high) + RT  7.0  (5–9)  10.3  0.001 vs. RAD, 0.392 vs. VEGF Trap (high), 0.014 vs. VEGF Trap (low) + RT
Abbreviations: %Δ daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
Table 4. VEGF Trap sequenced post–fractionated radiation: Summary of tumor growth (Schedule IV)
Treatment  %Δ (95% CI)  T2x  p values
Control (human FC protein)  31.5  (28–35)  2.5
RT (3 x 5 Gy)  15.0  (13–17)  5.1  0.001 vs. control, 0.460 vs. VEGF Trap (low), 0.001 vs. VEGF Trap (high)
VEGF Trap (2.5 mg/kg)  16.0  (13–19)  4.7  0.001 vs. control, 0.460 vs. RT alone
VEGF Trap (10 mg/kg)  8.0  (5–10)  9.2  0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGT Trap (low)
VEGF Trap (low) + RT  10.0  (7–12)  7.4  0.011 vs. RT, 0.001 vs. VEGF Trap (low)
VEGF Trap (high) + RT  5.5  (3–8)  12.8  0.001 vs. RT, 0.187 vs. VEGF Trap (high), 0.013 vs. VEGF Trap (low) + RT
Abbreviations: %Δ daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
concurrent treatment, and 32% for drug given postradiation treatment. 
Although high-dose VEGF Trap (either 10 mg/kg or 25 mg/kg) signifi-
cantly reduced tumor growth over that of radiation alone, there was no 
added benefit to combining high dose VEGF Trap with radiation. 
Effect of VEGF Trap and radiation on microvessel density 
Immunoassaying for endothelial cells with PECAM-1 revealed an inhi-
bition of tumor angiogenesis 3 weeks after treatment with VEGF Trap 
or VEGF Trap and radiation. Tumor MVD was similar in the control 
and radiation-treated tumors. Tumor MVD in the VEGF Trap treated 
tumors was decreased to between 43% to 57% of control or radiation-
treated tumors (p = 0.06). Tumor MVD in VEGF and radiation-treated 
groups decreased to between 15% and 30% of control or radiation-
treated groups (p = 0.001) (Fig. 7). There was no significant difference 
in MVD between high-dose VEGF Trap–treated with radiation vs. high 
dose VEGF Trap alone (p = 0.29). However, there was a significant 
difference in MVD between low-dose VEGF Trap-treated with radiation 
and low-dose VEGF Trap alone (p = 0.01, Fig. 8).
18-fluorodeoxyglucose–PET imaging of VEGF Trap–treated tumors
Figure 9a illustrates a series of images from a representative, untreated 
mouse. Figure 9b represents a series of images from a representative 
mouse treated with VEGF Trap dosed at or 10 mg/kg every 3 days 
(starting at Day 0) for 3 weeks. Tumor volume (mm3) and days following 
start of treatment are indicated. Because of the difficulty in matching 
tumor volumes and time after treatment, the percent of metabolically 
inactive tumor volume (as measured by FDG uptake) was measured as 
a function of tumor volume and averaged over a range of tumor volumes 
between 900 and 1,600 mm3. The percent of metabolically inactive 
tumor was significantly less in untreated tumors (2.46% ± 0.18%) than 
in tumors treated with 10 mg/kg VEGF Trap (8.7 ± 1.26%, p = 0.01) but 
not significantly different from tumors treated with 2.5 mg/kg VEGF 
Trap (3.36 ± 0.36%, p = 0.13) .
Discussion
This work demonstrated that VEGF Trap alone is an effective dose-
dependent inhibitor of tumor growth in U87GBM. These findings 
agreed with previous studies of VEGF Trap in other preclinical animal 
models demonstrating efficacy in halting angiogenesis and shrinking 
tumors30. Because VEGF Trap was very potent by itself and could have 
potentially masked any additional benefits of radiation, both low-dose 
and high-dose scheduling of the drug were used with radiotherapy. 
In all scheduling protocols that were investigated, the combination of 
low-dose VEGF Trap with radiation was significantly better than either 
treatment modality alone. On the other hand, high-dose VEGF Trap 
was significantly better than radiation alone and therefore masked any 
additional benefit that may have resulted from combination therapy.
The benefit of combined treatment with low VEGF Trap and radiation 
relative to radiation alone was not influenced by scheduling protocol. 
This result was in contrast to earlier work demonstrating improved 
radiation response when a VEGFR2 blocker, DC101, was given 4 to 
6 days before radiotherapy32. This earlier work suggested that tumor 
vasculature normalization occurred during pretreatment with the 
VEGFR2 blocker, a process in which pruning of immature and inef-
ficient blood vessels occurs leading to improved tumor perfusion and 
oxygenation and improved radiation response. The current observations 
may reflect the absence of a normalization effect by VEGF Trap on U87 
GBM vasculature or a missed window of opportunity for normalization 
because of the particular protocols used in this work. Because it is not 
known how tumor oxygenation levels may have varied throughout the 
course of combined treatment with VEGF Trap and radiation, addi-
tional studies are warranted to resolve the issue of normalization.
The observation that scheduling did not have an impact on efficacy of 
combined treatment with VEGF Trap and radiation in this study is also 
in contrast to recent studies in which VEGF blockade was obtained either 
by a VEGF receptor2 tyrosine kinase inhibitor, ZD6474, or indirectly by 
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Radiotherapy
HIF-1 alpha blockade of VEGF secretion. In both these studies, optimal 
antitumor efficacy was obtained when VEGF blockers were sequenced 
following radiation2, 33. These studies suggested that prolonged suppres-
sion of radiation-induced angiogenesis account for enhanced efficacy 
of combined treatments with angiogenesis blockade and radiation. 
However, it is not clearly understood why there is a difference in the 
impact of scheduling among these agents.
This work is encouraging in that it demonstrates for the first time a 
benefit in combining VEGF Trap with ionizing radiation in a highly resis-
tant GBM tumor model. VEGF Trap is a unique human fusion protein 
with very potent binding affinity for VEGF A isoforms as well as placental 
growth factor (PIGF) and is currently in clinical trials. Its affinity for 
VEGF is potentially 100- to 1,000-fold higher than existing VEGF mono-
clonal antibodies such as bevacizumab34. This high-affinity blockade of 
VEGF differentiates VEGF Trap from other anti-VEGF strategies and 
therefore gives this drug the potential to enhance combination modality 
treatment with lower dosing.
Mechanisms of enhanced U87 tumor control by combined therapy with 
VEGF Trap and radiation most likely include inhibition of radiation-
induced angiogenesis by VEGF Trap sequestration of circulating VEGF 
in the bloodstream and in the extracellular tumor space resulting from 
radiation-induced secretion. Indeed, in this study, a radiation-dose-
dependent increase in VEGF secretion by U87 glioblastoma cells was 
observed and excess VEGF was bound in the presence of VEGF Trap. In 
addition, immunohistochemical findings indicated a reduction in MVD 
3 weeks following treatment with VEGF Trap and radiation. Inhibition 
of radiation-induced angiogenesis was also observed indirectly through 
FDG–PET imaging, which revealed an increase in metabolically inac-
tive tumor tissue after VEGF Trap treatment, possibly arising from the 
induction of tumor necrosis or apoptosis in the presence of angiogenesis 
inhibition. It is also of interest that in this study, a brief period of fraction-
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Figure 7. Effect of vascular endothelial growth factor (VEGF) Trap 
and radiation (RT) (Schedule II) on microvessel density (MVD). 
Tumor MVD in VEGF Trap–treated tumors was decreased to 
between 43% and 57% of control or RT-treated tumors (p = 0.06). 
Tumor MVD in VEGF Trap and RT-treated groups decreased to 
between 15% and 30% of control or RT-treated groups  (p = 0.001). 
There was no significant difference in MVD between VEGF Trap–
treated (high dose) + radiation vs. VEGF Trap (high dose) alone 
(p = 0.29). However, there was a significant difference in MVD 
between VEGF Trap (low dose) + radiation and VEGF Trap (low 
dose) alone (p = 0.01).
Control VEGFT L VEGFT H
Radiation VEGFT L + R VEGFT H + R
Figure 8.  Platelet– endothelial cell adhesion molecule 1 (PECAM-
1) staining in subcutaneous U87 glioblastoma xenografts treated 
with vascular endothelial growth factor (VEGF) Trap with and 
without radiation therapy (Schedule II). Lower microvessel density 
(MVD) and altered vessel morphology were observed in treated 
tumors. (VEGFT L = VEGF Trap low dose; VEGFT H = VEGF Trap 
high dose; R = radiation) Original magnification: X 100.
A
B
*Volume (mm3) / (days
post-treatment)
Figure 9. 18-fluorodeoxyglucose (FDG)–PET imaging of human 
U87 glioblastoma xenografts in nude mice. (a) A series of typical 
images from an untreated mouse. (b) A series of images from a 
mouse treated with vascular endothelial growth factor (VEGF) 
Trap dosed at 10 mg/kg every 3 days (starting at Day 0) for 3 weeks. 
Tumor volume (mm3) and days following start of treatment are 
indicated. Imaging was performed as described in Methods and 
Materials. The percent of metabolically inactive tumor (as measured 
by FDG uptake) was significantly less in untreated tumors than in 
tumors treated with 10 mg/kg VEGF Trap.
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ated radiotherapy with VEGF Trap resulted in tumor growth retardation 
but not remission. The lack of remission is probably related to continued 
production of VEGF after removal of drug and radiation and points to 
the need for chronic therapy with VEGF Trap, which is in agreement with 
what has been observed for the transient effects of other antiangiogenic 
agents on tumor control23, 35.
In conclusion, these studies demonstrate that the combination of low-
dose VEGF Trap and radiation is clearly better than radiation alone in 
a U87 subcutaneous xenograft model. Although high doses of VEGF 
Trap alone are highly efficacious, it is unclear whether such high doses 
can be used clinically without incurring normal tissue toxicities. Thus, 
information on lower doses of VEGF Trap and ionizing radiation are of
clinical relevance.
It is understood that the SC xenograft model used in this study has 
shortcomings in that ectopic tumors implanted SC in the hind limb of 
animals do not duplicate the vascular microenvironment of orthotopic 
brain implants36. However, the use of hind limb injection is the standard 
approach for xenograft studies with radiation. In addition, human xeno-
grafts in immunocompromised nude mice, whether they be ectopic or 
orthotopic, both have deficiencies in that they can only approximate the 
human patient situation and seldom reflect accurately the glioblastoma 
multiforme histopathology seen in patients. This study is encouraging in 
that it demonstrates for the first time a benefit in combining VEGF Trap 
with ionizing radiation and warrants further investigations both preclini-
cally and clinically.
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